Tyme shares tumble after pancreatic cancer data

Tyme Technologies Inc. (NASDAQ:TYME) lost $1.32 (35%) to $2.41 on Jan. 18 after the company reported preliminary data from the open-label Phase II Tyme-88-Panc trial. The company said that once-daily oral SM-88 as monotherapy showed a "substantially improved" survival benefit over historical controls in a cohort of heavily pretreated patients with actively progressing metastatic pancreatic cancer who had received a median of two prior systemic therapies.

At a median follow-up of 4.3 months, 19 of 28 (68%) evaluable patients who received SM-88 remained alive. By line of therapy, three of four (75%) patients who received SM-88 as second-line treatment were alive at a median follow-up of 5.7 months; 11 of 14 (79%) patients who received SM-88 as third-line treatment were alive at a median follow-up of 4.7 months; and five of 10 (50%) patients who received SM-88 as fourth-line treatment were alive at a median follow-up of 3.5 months...